Skip to main content

Tweets

#AI can be a valuable tool, but needs to be reliable. Lupus100 and #lupusGPT created with vetted sources, #Easylupus is condensed, even more easy to read It's better to ask your patients to use it as a reliable source! #EULAR2025 @RheumNow https://t.co/FbYYm1dB8E
Bella Mehta @bella_mehta ( View Tweet )
7 months 2 weeks ago
Debuting Fishbowl sessions at #EULAR2025 🔄💊 Lively audience engaging session in A1 on how drug prices influence treatment decisions; real-world tensions between cost, access, & physician autonomy. Transparent, interactive, and packed! @RheumNow | Location: A1 | #EULAR2025 https://t.co/jVbviLuTZK
Jiha Lee @JihaRheum ( View Tweet )
7 months 2 weeks ago
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty

Dr. John Cush @RheumNow ( View Tweet )

7 months 2 weeks ago
#MTX in new #PMR?! RCT of #MTX was negative in early #PMR - no effect on #steroid #tapering ACR24 #1697 At #EULAR2025 👇 +RCT of #methotrexate in PMR <8wks #steroids #Rx MTX 25 mg/wk v #placebo N=64 ⬆️GC remission ✅80% v 46% ⬇️relapse w MTX 🤔 Abst0064 @RheumNow #EULAR2025

Janet Pope @Janetbirdope ( View Tweet )

7 months 2 weeks ago
#EULAR2025 Opening Plenary C. Dejaco, the EULAR Congress chair presents the @eular_org congress in numbers: 4 days 300+ Invited speakers 170+ Scientific sessions 40 Oral presentations 8 Poster tours 12000+ Attendees @RheumNow https://t.co/hX1ABtSio2
Aurelie Najm @AurelieRheumo ( View Tweet )
7 months 2 weeks ago
#EULAR2025 Abstr#POS0677 I will be at Poster Area today (1530). Single centre (N=23): Rituximab vs Cyclophosphamide for #Sjogren-Neuropathy. No superiority but clinical response was more complete & longer retention numerically favouring RTX. Support trial of BCDT in SjD @RheumNow https://t.co/87e6yFMRkk
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
7 months 2 weeks ago
Risk of #VTE in #rheumatoid #arthritis Is it better over last 25 yrs? 👎 Olmstead County population study of #RA Pts vs matched controls ⬆️VTE in RA ⬆️VTE w active RA But not change in rates of #DVT & #PE since 2000 Why? 🤔 Abst#OP0070 @rheumnow #EULAR2025 @eular_org https://t.co/eSyjfjVqtY
Janet Pope @Janetbirdope ( View Tweet )
7 months 2 weeks ago
135 pts w/ neurologic autoimmune dz (MS, GBS, myasthenia gravis) who had cancer & Rx w/ checkpoint inhibitors (ICI) showed exacerbations in SOME - 18% of MS pts, but 67%of MG, latter often w/ hospitalization (50%) or death (17%). GBS faired well w/ ICI Rx. https://t.co/RksC6QXce0 https://t.co/mYjzgxbcdQ
Dr. John Cush @RheumNow ( View Tweet )
7 months 2 weeks ago
UK Natl Early Inflammatory Arthritis Audit (5/18-11/19) compared 2120 PsA & RA (1:1). PsA had longer Sx to referral wait (112 v 89 days; HR 0.87), longer delay in Dx (HR 0.8), PsA less DMARD use at baseline (54% v 69%) & higher DAS28 results at 3 mos (+0.27) https://t.co/zyubhGxw47
Dr. John Cush @RheumNow ( View Tweet )
7 months 2 weeks ago
Rheums! Have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/f3nm9awojS https://t.co/dOaVZpDAWH
Dr. John Cush @RheumNow ( View Tweet )
7 months 2 weeks ago
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty.

Dr. John Cush @RheumNow ( View Tweet )

7 months 2 weeks ago
Single center Italian study of 414 JIA q6mos (for 2 yrs) used machine learning & 68 clinical variables to predict clinically inactive Dz (CID). Best predictive of CID at 2 yrs was 1) physician’s global assessment, followed by 2) active joint counts (using data from 0-12 mos) https://t.co/2SEH1a85Nj
Dr. John Cush @RheumNow ( View Tweet )
7 months 2 weeks ago
×